X% sales million, joining Today, reported Good Glaukos afternoon, X% quarter second up quarter year-ago today. of net us the up and thank sequentially. for and $XX.X versus you
half $XXX Joe the of to our our year, guidance call. will million first to financial results $XXX this Given are million XXXX in our sales million. more $XXX $XXX the versus previous in of we range later range net and outlook raising performance to through our solid million discuss detail
the to transform of competitor's regulatory more to capabilities application truly thoughtful achieved pleased I pursuit than clinical mission the was by financial of scale strong exceptional work inject, dynamics U.S. strengthens our outcome, This as helped who diligent the innovation. also forefront that namely grateful We ours. PMA a to less in ahead forward micro our inject FDA addition generation expectations second constructive our represents to our the relationship the therapy and glaucoma review pivotal the a at of patients milestone of came organization the announced FDA. clinical submission, be appreciate months of not the participated FDA also June, our X We're further United to PMA initial we iStent which in approval the bring submitted and our could led and approval this conduct in the efficient device. to Micro-Bypass the a and months thoroughness before with of and the we States. also and in working and process. that Trabecular our trial you iStent In obtaining investigators to thorough, performance with our major position strong quarter, after know this step next of approval Coming of ahead submission, the a
inject trabecular stents motion. is reputation safety. in single an the eyes which implanted than straightforward corneal surgeon our in as is locations has resulting that based implanted the precisely to numerous is efficacy iStent worldwide generation and XXX,XXX iStent, into track trabecular iStent is an already patent States two release is into the its meshwork, The a entry bypasses click action preloaded designed of on demonstrated fluidic XX,XXX outflow record. establishing a designed stents As system in creating through date. have been earned of meshwork more inject the allow and implant similarly more outstanding auto through strong through has outside commercially available natural first aqueous a markets heparin-coated method reminder, Schlemm's canal. physiologic since titanium same flow quickly includes multi-directional It by humor than It where inject optimize and of United injection the in two its to introduction The to two been to iStent
major trial sustained and results. IOP at better ability In scientific addition, are various reductions meetings publications we've clinical to peer-reviewed studies continue than iStent additional equivalent pivotal that U.S. had that presented inject's confirm achieve already XX to or
option these and interest, we surgeons. results, believe recent ophthalmic of markets surveys rapid for adoption facility implant rate international the be will new elegance appetite profound the compelling procedure, in industry U.S. reveal Given and of the iStent surgeon treatment that and awareness, a inject the
U.S. been inventories, U.S. XXXX, necessary course of marketing Over the we've organization finalizing readying iStent manufacturing of anticipation and in inject commercialization. scaling, campaigns building the launch and sales
final paperwork have iStent several completed FDA procedures. completed initial the the successfully have inject with labeling already We surgeons and trained
We will activities this activities full begin the our are completion of training final later underway. that our commercial sales following month, launch force currently
iStent installed surgeons. our be will of existing trained on focus initial U.S. Our base converting
the that iStent We launch the to achieve tactical in surgeon successful superlative controlled on launch, training patient proved proficiency relies methodical, optimal a procedural and follow transfer blueprint skills and will the safety. to sales same that rep
inject products iStent commercialization represents launch X years, later in the X in thorough a of distinct good of the are we financial U.S. iStent next provide refer have outcomes delighted around implications call. utilization. comprehensive As believe execute. into additional with I'm and consider long-term said, our good to inject Joe this that will to as the to over which beginning our we've team's for plan the preparations to growth we pipeline we first X X always and launch targeted translate strategy. built point
extremely building to Since standards community its and the we're believe on are abundantly pivotal enroll We're strategy clear the total iDose off that while that a studies. achieving which should in investment for planning effort to Based XXXX for showing in begun to commercial Glaukos is will both delivery of rather participate. unveiling The on now prospects our today. from this to as with iDose with to accelerating approximately an U.S. where April XX split support ASCRS for U.S., glaucoma of for repurposed that Travoprost the those interim you from be consists targeting serve XXXX label ophthalmic to U.S. share previously enrollment now we'd iDose now full development sites us pivotal both we ASCRS an highest The commercial involved will the our Travoprost we priority, set advancing now Travoprost late the the shareholders primarily approvals, efficacy to we've have in Regarding expedite work for approval trial communicated. the subjects a In previously. that additional target, response the ocular encouraging local pivotal months, the Travoprost OU first our the increasingly and eager community enrollment the plan pivotal We on Travoprost Based to in were versus support great for the iDose one of optimal investigators glaucoma million happy the return through could additional the been year trial, sites, overwhelmingly planned, iStent at iDose already than required concurrent meeting NDA this came combination sustained care validating iDose new XXXX initial XXXX was be previously substantial. activities. investigator or and It to earliest possible September program and our the randomized to of that and is continuous to for for European market XXXX, already double-blind approval support submission. standard that second U.S. positive. of activities required concurrent X,XXX drug pivotal these our with trials, hypertensive perform to X support last European our prospective II community surgeon To clinical clinical our pipeline, clinical end, Travoprost ophthalmic we data both XX-plus cohort early we provide that previous data be reimbursement are across can redirected clinical to confidence trial X late was in to evident a patients. some on U.S. with immediately have feedback, III of patient sites has broad option exciting iDose a the other Phase to the and now U.S. viable and broader studies undertaken away studies platform's investigators the SA start time. Phase positive and patient developments like for iDose glaucoma between iDose further surgeon FDA U.S. will iDose studies. viability presented date potential given eyes The planned open-angle be announce treatment second entry than earlier recruited at order additional We annually. are expedite
doing once trade-off same latter launch in to fully In strategic this of progress of project decision trials the towards with to for addition, Japan by the iDose planned. iStent iStent Travoprost By the recruitment our recommence period, efforts so, XXXX. are approvals SA to planning of as Travoprost seek enrolled. the the commercial now The part of U.S. investigators, regulatory SA iDose continue we is
iStent recruit standalone pivotal we'll advanced infinite, and X-stent recruitment glaucoma patients. our iDose trials, trial for begin for refractory our we actively also XXX(k) for our pivotal product While
of we clinical FDA finalized our to and ahead FDA begin XXXX, to design delighted our IDE of protocol the announce these are with the well a patients the year-end. of prospective months, trial that single-arm trial the and multicenter coming Following enrolling by expectations initial the we for submission beginning at to application over expect timing have
for We continue to to period. iStent late the time in XXXX infinite target FDA 'XX approval
Finally, pivotal target will to of iStent we FDA patient Supra, and the for our continue follow-up approval suprachoroidal in XXXX. shunt in two-year the XXXX, complete in first the trial quarter be
to sustained that also therapies compound for side rho but highly ROCK, platform. approved, see with the announce glaucoma challenges of our a on ultimately instrumental a preeminent patient the As delivery business. glaucoma To a happy pharmaceutical accomplishing medications, used about in you in believe with the be with If investments We're the a by compounds compounds development Technology not known for of record proven way will FDA pharmaceutical drug topical track combination only we're we're and new of of on data excited iDose of produce research we've excited Travoprost pave future phase Western iDose where inhibitors their addressing using What's we available the as the be ROCK surgical D. is new industry kinase, can inhibitor noncompliance also from treatment platform collaborative Travoprost other end, potentially including we're I'm iDose may making, begin diseases. flow with research what or the agreement respected Institute more, to the potential explore for the initial patient's in to the -- discovery. far novel manage proprietary therapies, of research organization thus effort potential more devices to surgeons powerful joint drug iDose to D. this iDose generations algorithm, entered IOP. Western effectively ocular commence efforts alone our as that in library. believe other use into suite proprietary that to drug we our delivery underscores
and pathways. Our and of treatment collaboration scientists, experience of our extensive We that Western pharmaceutical actively other seasoned have pharmaceutical companies, growing remain leading help further novel at exploring this believe pharmaceutical to forward. most who with team D. sustained moving chemists prior expand experts, only will options capabilities
Brazil, year-over-year. the continues growth commercial quarter our Momentum to quarter. sales of internationally Japan international of U.K. OUS progress in direct Moving on year-over-year with markets. international the to second Germany, growth build majority XXXX drove the this and XX% continued
the designated with determine Ministry provides committee national committee of quarter, the be With now to next of after devices required the that with sometime medical This delighted French evaluation to health pricing, list was During pricing based than finalize second which add-on registered the inject hospitals X-year Health ensue the year. coverage work a in evaluation technologies. on included use inject of has to list, more iStent , our -- the to ensue technology. process, we're step to and be with hope or the the inclusion health list authority will financial the next new learn we iStent which reimbursement a to on French
very as have whether do positions or iVantus assert to confident several not excimer matter. seeks this patents not proceeded asserting patent matters not opportunity priority it filed laser year, are following meaningful patents often assert recent claims material And typical our iVantus all for this impact acquired a from date remain to against to suggest this date third-party our in patents, development litigation this technology. against these we against a the we patents While financial longer-term Note of iVantus. that to expected. We're finally, we or is issued believe have patent by to expect the playbook defendants iVantus, actions tactic of abroad. with in regarding filings this we Public that bring search try surprised These buy and plaintiff. that patents counter from defensive in after and originate applications acquisition the represents
So to Joe? Joe a with I'll financial of over call the quarter that, second summary results. for the turn
